LFVN · CIK 849146
What LifeVantage Corporation told the SEC could break it.
LifeVantage's disclosures revolve around its concentration in a few products sold through a direct-selling model. Its Protandim, LifeVantage and TrueScience lines together made up about 87.6% of fiscal 2025 revenue, so a regulatory, reputational or demand setback to those products would be highly damaging. Its direct-selling, independent-consultant structure exposes it to FTC scrutiny of its compensation plan and its supplements to FDA oversight, either of which could bar it from markets. It also flags roughly 22% of revenue from international operations (Japan about 11%), where currency swings hurt fiscal 2025 results, and difficulty or expense in sourcing high-quality raw materials, for which it keeps secondary and tertiary suppliers as a hedge.
4 self-disclosed vulnerabilities, pulled from its own filings, each in the company’s words, with the source. This is the risk register almost nobody reads.
In its own words
What could break it.
Other disclosures
- product concentration — Protandim/LifeVantage/TrueScience lines = 87.6% of revenuehigh
LifeVantage relies on a few product lines — Protandim, LifeVantage and TrueScience — for ~87.6% of total fiscal-2025 revenue, so any adverse impact to those products (regulatory, reputational, demand) would be highly damaging.
“We primarily rely on our Protandim ® , LifeVantage ® , and TrueScience ® product lines for a majority of our revenue, which collectively represent approximately 87.6% of total revenue for the fiscal year ended June 30, 2025.”
SEC filing →As of 2025
Currency (FX)
- international operations (~22% of revenue, Japan 11%) — currency and trade exposuremedium
About 22% of LifeVantage's revenue is international (mostly Japan at ~11%); foreign-currency fluctuations negatively impacted fiscal-2025 net revenue, and it faces trade/tariff and foreign-exchange restriction risks (it closed its Philippines market in 2025).
“In fiscal year 2025, we generated approximately 22% of our revenue from our international operations, a majority of which was generated in Japan.”
SEC filing →As of 2025
Supplier concentration
- difficulty/expense sourcing high-quality raw materials; reliance on secondary/tertiary suppliersmedium
LifeVantage notes that high-quality material for its products may be difficult or expensive to obtain, and it maintains relationships with secondary and tertiary suppliers as a hedge — a raw-material sourcing/availability risk for its supplements.
“Please refer to “ Risk Factors - High quality material for our products may be difficult to obtain or expensive ” for a discussion of the risks and uncertainties associated with our sourcing of raw materials.”
SEC filing →As of 2025
Regulatory & policy
- direct-selling/MLM regulation (FTC) and FDA dietary-supplement ruleslow
LifeVantage's direct-selling/independent-consultant model could be found non-compliant with current or new laws (FTC scrutiny of its compensation plan), and its supplements face FDA oversight (warning letters, seizure, product-claim limits) — either could bar it from markets.
“Our direct selling program could be found to be not in compliance with current or newly adopted laws or regulations in one or more markets, which could prevent us from conducting our business in these markets and harm our financial condition and operating results.”
SEC filing →As of 2025
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch